One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients
•Dulaglutide has proven efficacy and safety in patients with diabetic kidney disease.•Dulaglutide showed sustained efficacy during the initial 1 year of treatment.•Dulaglutide could be a favorable long-term therapeutic option for patients with diabetic kidney disease. Dulaglutide is a long-acting gl...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2024-09, Vol.46 (9), p.683-688 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 688 |
|---|---|
| container_issue | 9 |
| container_start_page | 683 |
| container_title | Clinical therapeutics |
| container_volume | 46 |
| creator | Kim, Myung Jin Kim, Hwi Seung Cho, Yun Kyung Jung, Chang Hee Lee, Woo Je |
| description | •Dulaglutide has proven efficacy and safety in patients with diabetic kidney disease.•Dulaglutide showed sustained efficacy during the initial 1 year of treatment.•Dulaglutide could be a favorable long-term therapeutic option for patients with diabetic kidney disease.
Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys and has proven efficacy and safety in patients with diabetic kidney disease. We aimed to evaluate the 1-year efficacy of dulaglutide in patients with diabetic kidney disease who have used the drug for more than 1 year.
This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023. The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals. Subgroup analyses were conducted based on age, sex, baseline body mass index, FPG, and HbA1c, and insulin administration at baseline and last follow-up.
The mean age was 60.0 ± 10.2 years, and 61.1% of the participants were males. Baseline HbA1c, FPG, and body weight were 9.1% (76.0 mmol/mol), 186.8 mg/dL, and 79.3 kg, respectively. Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: –1.2 ± 0.1%, –34.8 ± 6.9 mg/dL, and –2.3 ± 0.5 kg, respectively; P < 0.001). Subgroup analysis revealed significant differences in HbA1c reduction based on baseline HbA1c.
Dulaglutide exhibited sustained glucose-lowering and weight-reduction effects during the initial 1 year of treatment in patients with diabetic kidney disease. Altogether, dulaglutide could serve as a favorable long-term therapeutic option for patients with diabetic kidney disease in real-world clinical settings. |
| doi_str_mv | 10.1016/j.clinthera.2024.06.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3085685681</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291824001991</els_id><sourcerecordid>3103224955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c275t-306c3676e886da1825370630f180bea1f05d083b7b72ebb9fc6a8b25918d164d3</originalsourceid><addsrcrecordid>eNqFkcFu1DAURS0EokPhF8ASGzYJz3biJOxG0wIVlYpokdhZjv3CeJRJprZTlL_gk_F02iJ1U8nSXfjc9-x7CXnHIGfA5MdNbno3xDV6nXPgRQ4yT_KMLFhdNRljxa_nZAGsaDLesPqIvAphAwCiKflLciQakE0h-IL8vRgwm1F7etp1zmgzUz1Yeqk7jDMdO3oy9fp3P0VnkbqBftfR4RAD_ePiml7NO6ScnjjdYsRwa12t_Tg4Q785O-Cc7gLqgJ_okv7A6MewQxPdDdLLONnbDcvg9P_Br8mLTvcB39zpMfn5-fRq9TU7v_hytlqeZ4ZXZcwESCNkJbGupdWs5qWoQAroWA0tatZBaaEWbdVWHNu26YzUdcvLFIZlsrDimHw4zN358XrCENXWBYN9rwccp6AE1KXcH5bQ94_QzTj5Ib1OCQaC86Ipy0RVB8qkTwaPndp5t9V-VgzUvjS1UQ-lqX1pCqRKkpxv7-ZP7Rbtg---pQQsDwCmQG4cehVMCsugdT6lqezonlzyD1DxrBw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3103224955</pqid></control><display><type>article</type><title>One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Kim, Myung Jin ; Kim, Hwi Seung ; Cho, Yun Kyung ; Jung, Chang Hee ; Lee, Woo Je</creator><creatorcontrib>Kim, Myung Jin ; Kim, Hwi Seung ; Cho, Yun Kyung ; Jung, Chang Hee ; Lee, Woo Je</creatorcontrib><description>•Dulaglutide has proven efficacy and safety in patients with diabetic kidney disease.•Dulaglutide showed sustained efficacy during the initial 1 year of treatment.•Dulaglutide could be a favorable long-term therapeutic option for patients with diabetic kidney disease.
Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys and has proven efficacy and safety in patients with diabetic kidney disease. We aimed to evaluate the 1-year efficacy of dulaglutide in patients with diabetic kidney disease who have used the drug for more than 1 year.
This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023. The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals. Subgroup analyses were conducted based on age, sex, baseline body mass index, FPG, and HbA1c, and insulin administration at baseline and last follow-up.
The mean age was 60.0 ± 10.2 years, and 61.1% of the participants were males. Baseline HbA1c, FPG, and body weight were 9.1% (76.0 mmol/mol), 186.8 mg/dL, and 79.3 kg, respectively. Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: –1.2 ± 0.1%, –34.8 ± 6.9 mg/dL, and –2.3 ± 0.5 kg, respectively; P < 0.001). Subgroup analysis revealed significant differences in HbA1c reduction based on baseline HbA1c.
Dulaglutide exhibited sustained glucose-lowering and weight-reduction effects during the initial 1 year of treatment in patients with diabetic kidney disease. Altogether, dulaglutide could serve as a favorable long-term therapeutic option for patients with diabetic kidney disease in real-world clinical settings.</description><identifier>ISSN: 0149-2918</identifier><identifier>ISSN: 1879-114X</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2024.06.024</identifier><identifier>PMID: 39069432</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Analysis of covariance ; Antidiabetics ; Body mass index ; Body weight ; Chronic kidney disease ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Dulaglutide ; Glomerular filtration rate ; GLP-1 receptor agonist ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Hemoglobin ; Insulin ; Kidney diseases ; Mortality ; Patients ; Thyroid gland ; Type 2 diabetes mellitus ; Variance analysis</subject><ispartof>Clinical therapeutics, 2024-09, Vol.46 (9), p.683-688</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><rights>2024. The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c275t-306c3676e886da1825370630f180bea1f05d083b7b72ebb9fc6a8b25918d164d3</cites><orcidid>0000-0002-1899-3560</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291824001991$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39069432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Myung Jin</creatorcontrib><creatorcontrib>Kim, Hwi Seung</creatorcontrib><creatorcontrib>Cho, Yun Kyung</creatorcontrib><creatorcontrib>Jung, Chang Hee</creatorcontrib><creatorcontrib>Lee, Woo Je</creatorcontrib><title>One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>•Dulaglutide has proven efficacy and safety in patients with diabetic kidney disease.•Dulaglutide showed sustained efficacy during the initial 1 year of treatment.•Dulaglutide could be a favorable long-term therapeutic option for patients with diabetic kidney disease.
Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys and has proven efficacy and safety in patients with diabetic kidney disease. We aimed to evaluate the 1-year efficacy of dulaglutide in patients with diabetic kidney disease who have used the drug for more than 1 year.
This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023. The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals. Subgroup analyses were conducted based on age, sex, baseline body mass index, FPG, and HbA1c, and insulin administration at baseline and last follow-up.
The mean age was 60.0 ± 10.2 years, and 61.1% of the participants were males. Baseline HbA1c, FPG, and body weight were 9.1% (76.0 mmol/mol), 186.8 mg/dL, and 79.3 kg, respectively. Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: –1.2 ± 0.1%, –34.8 ± 6.9 mg/dL, and –2.3 ± 0.5 kg, respectively; P < 0.001). Subgroup analysis revealed significant differences in HbA1c reduction based on baseline HbA1c.
Dulaglutide exhibited sustained glucose-lowering and weight-reduction effects during the initial 1 year of treatment in patients with diabetic kidney disease. Altogether, dulaglutide could serve as a favorable long-term therapeutic option for patients with diabetic kidney disease in real-world clinical settings.</description><subject>Analysis of covariance</subject><subject>Antidiabetics</subject><subject>Body mass index</subject><subject>Body weight</subject><subject>Chronic kidney disease</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Dulaglutide</subject><subject>Glomerular filtration rate</subject><subject>GLP-1 receptor agonist</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Hemoglobin</subject><subject>Insulin</subject><subject>Kidney diseases</subject><subject>Mortality</subject><subject>Patients</subject><subject>Thyroid gland</subject><subject>Type 2 diabetes mellitus</subject><subject>Variance analysis</subject><issn>0149-2918</issn><issn>1879-114X</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcFu1DAURS0EokPhF8ASGzYJz3biJOxG0wIVlYpokdhZjv3CeJRJprZTlL_gk_F02iJ1U8nSXfjc9-x7CXnHIGfA5MdNbno3xDV6nXPgRQ4yT_KMLFhdNRljxa_nZAGsaDLesPqIvAphAwCiKflLciQakE0h-IL8vRgwm1F7etp1zmgzUz1Yeqk7jDMdO3oy9fp3P0VnkbqBftfR4RAD_ePiml7NO6ScnjjdYsRwa12t_Tg4Q785O-Cc7gLqgJ_okv7A6MewQxPdDdLLONnbDcvg9P_Br8mLTvcB39zpMfn5-fRq9TU7v_hytlqeZ4ZXZcwESCNkJbGupdWs5qWoQAroWA0tatZBaaEWbdVWHNu26YzUdcvLFIZlsrDimHw4zN358XrCENXWBYN9rwccp6AE1KXcH5bQ94_QzTj5Ib1OCQaC86Ipy0RVB8qkTwaPndp5t9V-VgzUvjS1UQ-lqX1pCqRKkpxv7-ZP7Rbtg---pQQsDwCmQG4cehVMCsugdT6lqezonlzyD1DxrBw</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Kim, Myung Jin</creator><creator>Kim, Hwi Seung</creator><creator>Cho, Yun Kyung</creator><creator>Jung, Chang Hee</creator><creator>Lee, Woo Je</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1899-3560</orcidid></search><sort><creationdate>20240901</creationdate><title>One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients</title><author>Kim, Myung Jin ; Kim, Hwi Seung ; Cho, Yun Kyung ; Jung, Chang Hee ; Lee, Woo Je</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c275t-306c3676e886da1825370630f180bea1f05d083b7b72ebb9fc6a8b25918d164d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Analysis of covariance</topic><topic>Antidiabetics</topic><topic>Body mass index</topic><topic>Body weight</topic><topic>Chronic kidney disease</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Dulaglutide</topic><topic>Glomerular filtration rate</topic><topic>GLP-1 receptor agonist</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Hemoglobin</topic><topic>Insulin</topic><topic>Kidney diseases</topic><topic>Mortality</topic><topic>Patients</topic><topic>Thyroid gland</topic><topic>Type 2 diabetes mellitus</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Myung Jin</creatorcontrib><creatorcontrib>Kim, Hwi Seung</creatorcontrib><creatorcontrib>Cho, Yun Kyung</creatorcontrib><creatorcontrib>Jung, Chang Hee</creatorcontrib><creatorcontrib>Lee, Woo Je</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Myung Jin</au><au>Kim, Hwi Seung</au><au>Cho, Yun Kyung</au><au>Jung, Chang Hee</au><au>Lee, Woo Je</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>46</volume><issue>9</issue><spage>683</spage><epage>688</epage><pages>683-688</pages><issn>0149-2918</issn><issn>1879-114X</issn><eissn>1879-114X</eissn><abstract>•Dulaglutide has proven efficacy and safety in patients with diabetic kidney disease.•Dulaglutide showed sustained efficacy during the initial 1 year of treatment.•Dulaglutide could be a favorable long-term therapeutic option for patients with diabetic kidney disease.
Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys and has proven efficacy and safety in patients with diabetic kidney disease. We aimed to evaluate the 1-year efficacy of dulaglutide in patients with diabetic kidney disease who have used the drug for more than 1 year.
This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2 who had received dulaglutide for more than one year between June 2016 and May 2023. The primary outcome measures were changes in glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and body weight from baseline to the 12-month follow-up, with assessments performed at six-month intervals. Subgroup analyses were conducted based on age, sex, baseline body mass index, FPG, and HbA1c, and insulin administration at baseline and last follow-up.
The mean age was 60.0 ± 10.2 years, and 61.1% of the participants were males. Baseline HbA1c, FPG, and body weight were 9.1% (76.0 mmol/mol), 186.8 mg/dL, and 79.3 kg, respectively. Dulaglutide significantly reduced HbA1c, FPG, and body weight from baseline to the 12-month follow-up (mean ± standard error: –1.2 ± 0.1%, –34.8 ± 6.9 mg/dL, and –2.3 ± 0.5 kg, respectively; P < 0.001). Subgroup analysis revealed significant differences in HbA1c reduction based on baseline HbA1c.
Dulaglutide exhibited sustained glucose-lowering and weight-reduction effects during the initial 1 year of treatment in patients with diabetic kidney disease. Altogether, dulaglutide could serve as a favorable long-term therapeutic option for patients with diabetic kidney disease in real-world clinical settings.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39069432</pmid><doi>10.1016/j.clinthera.2024.06.024</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1899-3560</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2024-09, Vol.46 (9), p.683-688 |
| issn | 0149-2918 1879-114X 1879-114X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3085685681 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | Analysis of covariance Antidiabetics Body mass index Body weight Chronic kidney disease Diabetes Diabetes mellitus (non-insulin dependent) Dulaglutide Glomerular filtration rate GLP-1 receptor agonist GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Hemoglobin Insulin Kidney diseases Mortality Patients Thyroid gland Type 2 diabetes mellitus Variance analysis |
| title | One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T06%3A27%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=One-year%20Efficacy%20and%20Safety%20of%20Dulaglutide%20in%20Patients%20with%20Type%202%20Diabetes%20and%20Chronic%20Kidney%20Disease:%20A%20Retrospective%20Study%20of%20Asian%20Patients&rft.jtitle=Clinical%20therapeutics&rft.au=Kim,%20Myung%20Jin&rft.date=2024-09-01&rft.volume=46&rft.issue=9&rft.spage=683&rft.epage=688&rft.pages=683-688&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2024.06.024&rft_dat=%3Cproquest_cross%3E3103224955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3103224955&rft_id=info:pmid/39069432&rft_els_id=S0149291824001991&rfr_iscdi=true |